Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227610 · ClinicalTrials.gov registry record · Phase 2
Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)
A Phase 2 study of Brain Metastases and Cancer (With CNS Involvement), sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT07227610 is a Phase 2 study of Brain Metastases and Cancer (With CNS Involvement) that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 54 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07227610, a Phase 2 study of Brain Metastases and Cancer (With CNS Involvement), is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, phase II trial comparing staged stereotactic radiosurgery (SSRS) versus fractionated stereotactic radiotherapy (FSRT) in patients with large brain metastases (≥2 cm and ≤5 cm). The study aims to evaluate efficacy, safety, and tumor response between these two standard-of-care radiation approaches.
Conditions Studied
Interventions
- RADIATION Staged Stereotactic Radiosurgery (SSRS)
- RADIATION Fractionated Stereotactic Radiotherapy (FSRT)
Study Locations (1)
South Carolina
- Medical University of South Carolina Hollings Cancer Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2026-02-03 |
| Est. Completion | 2030-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227610
The ClinicalTrials.gov registry entry for NCT07227610 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (75% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Brain Metastases appearing as the primary indexed condition, and to 2 interventions - of which Staged Stereotactic Radiosurgery (SSRS) is the first listed.
NCT07227610 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT07227610 about?
NCT07227610 is a clinical study titled "Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)". This is a randomized, phase II trial comparing staged stereotactic radiosurgery (SSRS) versus fractionated stereotactic radiotherapy (FSRT) in patients with large brain metastases (≥2 cm and ≤5 cm). The study aims to evaluate efficacy, safety, and tumor response between these two standard-of-care ra...
What is the current status of trial NCT07227610?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2026-02-03. Estimated completion is 2030-02-03.
What conditions does trial NCT07227610 study?
This clinical trial studies the following conditions: Brain Metastases, Cancer (With CNS Involvement).
What interventions are being tested in trial NCT07227610?
The interventions under investigation include: Staged Stereotactic Radiosurgery (SSRS) (RADIATION), Fractionated Stereotactic Radiotherapy (FSRT) (RADIATION).
Who is sponsoring clinical trial NCT07227610?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227610 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.